NeuroVive reported results for Q1 with a loss of SEK 16.5m. It raised SEK 67m before issue cost and will be deciding on the SEK 20m direct issue to Hadean Ventures. The company has taken measures to minimise the impact of the covid-19 crisis of its projects. We think NeuroVive is on the right track.